

Title: The potential role of FREM1 and its isoform TILRR in HIV-1 acquisition through mediating inflammation

Mohammad Abul Kashem^{1,2}, Hongzhao Li^{1,3}, Lewis Ruxi Liu^{1,2}, Binhua Liang^{2,3,4}, Robert Were Omange⁵, Francis A. Plummer^{1††}, Ma Luo^{1,2,3*}

Authors' affiliation(s):

¹Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.

²JC Wilt Infectious Diseases Research Centre, Winnipeg, MB, Canada.

³National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.

⁴Department of Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, MB, Canada.

⁵Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States.

Running Title: FREM1 and TILRR in HIV-1 acquisition

††In memoriam

*Correspondence to: Ma Luo, PhD


JC Wilt Infectious Diseases Research Center, National Microbiology

Laboratory, 745 Logan Avenue, Winnipeg, MB, R3E 3L5, Canada;

Department of Medical Microbiology, University of Manitoba, Winnipeg,

MB, Canada; Phone: 204-789-5072, Fax: 204-789-2018

Email: ma.luo@canada.ca; Ma.Luo@umanitoba.ca



Supplementary Figure S1: PRISMA layout for searching the relevant literature. FREM1/TILRR related publications were rigorously searched in different databases including PubMed/Medline (OVID), EMBASE, Web of Science, Scopus, and Google Scholar using the University of Manitoba library (<https://libguides.lib.umanitoba.ca/az.php>). Specific search terms were used, such as FREM1, TILRR, and FREM1/TILRR in inflammation. Following the search of each database, total reported items were recorded and the duplicates were removed. Initial screening was done by reading the abstract of all reported items. Conference abstracts and data-only files that are part of full reports were excluded from this study. The full text of the remaining publications was thoroughly read and irrelevant publications were further excluded. Finally, the full-screened publications that directly adhered to the topic of interest were included in this review. This layout was adapted from Moher et al. [1].

Supplementary Table S1: PRISMA checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	N/A
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	N/A
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	2-3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	N/A
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3-4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	3-4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	3-4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	3-4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	3-4

Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	N/A
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	N/A
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	N/A
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	4
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	N/A
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	N/A
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	N/A
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	N/A
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	4-23
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	N/A
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	23
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	24

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097; For more information, visit: www.prisma-statement.org.

Reference

1. Moher D, Liberati A, Tetzlaff J, Altman DG: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.** *PLoS medicine* 2009, **6**(7):e1000097.